Key Points
- Biosig Technologies CIO Mitchell Young Williams sold 23,810 shares on June 1 at an average price of $1.05, for proceeds of about $25,000.50. The filing says the sale was made to cover tax withholding obligations tied to vesting equity awards.
- After the transaction, Williams still directly owned 3,013,838 shares of Biosig, worth about $3.16 million, and the sale trimmed his position by 0.78%. He also sold 263,863 shares on May 1 at an average price of $0.79.
- Biosig Technologies recently reported a quarterly loss of $0.27 per share, while analysts currently show mixed sentiment with a consensus rating of Hold and an average target price of $8.00.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) CIO Mitchell Young Williams sold 23,810 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $1.05, for a total value of $25,000.50. Following the transaction, the executive directly owned 3,013,838 shares in the company, valued at $3,164,529.90. This represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Mitchell Young Williams also recently made the following trade(s):
- On Friday, May 1st, Mitchell Young Williams sold 263,863 shares of Biosig Technologies stock. The stock was sold at an average price of $0.79, for a total value of $208,451.77.
Biosig Technologies Price Performance
Shares of STEX stock opened at $1.19 on Wednesday. The business's fifty day simple moving average is $1.12. Biosig Technologies, Inc. has a 1-year low of $0.70 and a 1-year high of $14.11. The firm has a market capitalization of $215.43 million, a price-to-earnings ratio of -0.12 and a beta of 1.85.
Biosig Technologies (NASDAQ:STEX - Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share for the quarter.
Wall Street Analyst Weigh In
Several research firms have weighed in on STEX. Needham & Company LLC lowered their target price on Biosig Technologies from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, May 21st. Wall Street Zen lowered Biosig Technologies from a "hold" rating to a "strong sell" rating in a report on Sunday, April 5th. Finally, Weiss Ratings raised Biosig Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $8.00.
Read Our Latest Report on STEX
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
